89891-65-6

Usage

Uses

Used in Scientific Research:
7-Bromo-2-chloroquinoxaline is used as a research compound for its unique chemical properties, allowing scientists to explore its potential in various chemical and biological studies.
Used in Medicinal Formulation:
7-Bromo-2-chloroquinoxaline is used as an intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Chemical Reactions:
7-Bromo-2-chloroquinoxaline is used as a reactant in various organic chemical reactions, enabling the synthesis of a wide range of compounds with different applications.
Used in Industrial Applications:
7-Bromo-2-chloroquinoxaline is used as a component in the production of certain industrial products, leveraging its chemical properties for specific uses in manufacturing processes.

Upstream product

• 82031-32-1 7-bromo-1H-quinoxalin-2-one 
• 924-44-7 glyoxylic acid ethyl ester 
• 95-54-5 1,2-diamino-benzene 
• 1196-57-2 2-hydroxyquinoxaline 
• 82031-32-1 2-hydroxy-7-bromoquinoxaline 
• 1196-57-2 quinoxalin-2⁽¹⁾-one 

Downstream Products

• 212327-11-2 7-bromoquinoxaline-2-amine 
• 705262-64-2 2-((7-bromoquinoxalin-2-yl)oxy)ethanol 
• 1271847-04-1 4-[3-(4-pyridin-4-yl-piperazin-1-yl)-quinoxalin-6-yl]-phenlamine 
• 1271846-98-0 4-(3-chloro-quinoxalin-6-yl)-phenol 
• 1271847-02-9 4-(3-morpholin-4-yl-quinoxalin-6-yl)-phenylamine 
• 1271829-25-4 7-(2-methoxy-phenyl)-2-morpholin-4-yl-quinoxaline 
• 1271836-50-0 4-(3-pyrrolidin-1-yl-quinoxalin-6-yl)-phenol 
• 1271838-58-4 2-phenyl-N-{4-[3-(4-pyridin-4-yl-piperazin-1-yl)-quinoxalin-6-yl]-phenyl}-acetamide 
• 1271847-00-7 N-[3-(3-chloro-quinoxalin-6-yl)-phenyl]-acetamide 
• 916811-87-5 4-(7-bromoquinoxalin-2-yl)morpholine 
• 1312448-32-0 N-(2-chloro-5-(3-(dimethylamino)quinoxalin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 1201842-02-5 N-(2-chloro-5-(3-morpholinoquinoxalin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 1201844-32-7 N-(2-chloro-5-(3-(pyridin-4-yl)quinoxalin-6-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide 
• 1380311-76-1 C₂₃H₂₅N₅O₂*ClH 

Relevant academic research and scientific papers

SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF

The disclosure provides substituted imidazo [1, 5-a] quinoxaline and related compounds as kinase inhibitors, and their uses. Specifically, the disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof or prodrugs thereof, wherein, A 1-A 3, Cy and R 1-R 2 are defined herein. The compounds of Formula I are kinase inhibitors. Therefore, the compounds of the disclosure can be used to treat clinical conditions caused by DDR function defects, such as cancers. (I)

Double-target inhibitor targeting FGFR (fibroblast growth factor receptor) and HDAC (histone deacetylase) as well as preparation method and application thereof, pharmaceutical composition and medicament

The invention discloses a double-target inhibitor targeting FGFR (fibroblast growth factor receptor) and HDAC (histone deacetylase) as well as a preparation method and application thereof, a pharmaceutical composition and a medicament, and belongs to the

SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF

The disclosure relates to substituted fused heteroaromatic compounds and the use thereof. Specifically, the disclosure provides compounds of the following Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A1-A4, B1-B3, D1-D4 and R1-R3 are defined herein. Compounds having Formula I are kinalse inhibitors. Therefore, compounds of the disclosure may be used to treat clinical conditions caused by DDR functional defects, such as cancer.

TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT

Pharmaceutical compounds, their methods of manufacture, and methods of treatment of mammals with pharmaceutical compounds are provided.

NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS

The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

PYRIMIDINE AND TRIAZINE DERIVATIVES AND THEIR USE AS AXL INHIBITORS

Compounds of the general formula(I): (I) processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.